Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide and O6-BG in Temozolomide-Resistant Anaplastic Glioma
NCT00389090Phase 2Terminated
- Sponsor
- Keryx Biopharmaceuticals, Inc.
- Start
- Oct 2006
- Primary completion
- Jun 2008
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 6-benzylguanine in anaplastic glioma, sponsored by Keryx Biopharmaceuticals, Inc. Primary endpoint: Best Objective Response Rate. Started Oct 2006; status: terminated.
02
Drugs
6-benzylguanine
03
Conditions
anaplastic glioma
Beyond the preview
Go deeper on NCT00389090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00389090.